* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download بنام خداوند Useful drugs pharmacology in spinal anesthesia Dr
Drug design wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Epinephrine autoinjector wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Drug interaction wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmacokinetics wikipedia , lookup
بنام خداوند Useful drugs pharmacology in spinal anesthesia Dr siamak yaghoubi Anesthesiologist intensivist Clinical Pharmacology • Successful use of regional anesthesia requires knowledge of the pharmacologic properties of the various local anesthetic drugs. • Commonly used aminoester local anesthetics include procaine, chloroprocaine, tetracaine, and cocaine. • Commonly used aminoamides include lidocaine, mepivacaine, prilocaine, bupivacaine , ropivacaine, and etidocaine. • The ester and amide local anesthetics differ in their chemical stability, locus of biotransformation, and allergic potential. • Amides are extremely stable, whereas esters are relatively unstable in solution. • Aminoesters are hydrolyzed in plasma by cholinesterase enzymes, • but the amides undergo enzymatic degradation in the liver. • Two exceptions to this trend include cocaine, an ester that is metabolized predominantly by hepatic carboxylesterase, • and articaine, an amide local anesthetic widely used in dentistry that is inactivated by plasma carboxylesterase-induced cleavage of a methyl ester on the aromatic ring. • p-Aminobenzoic acid is one of the metabolites of ester-type compounds that can induce allergic-type reactions in a small percentage of patients. • The aminoamides are not metabolized to paminobenzoic acid, and reports of allergic reactions to these agents are extremely rare. General Considerations • Clinically important properties of the various local anesthetics include potency, speed of onset, duration of anesthetic action, and differential sensory/motor blockade. Anesthetic Potency • Hydrophobicity appears to be a primary determinant of intrinsic anesthetic potency because the anesthetic molecule must penetrate into the nerve membrane and bind at a partially hydrophobic site on the Na+ channel. • Clinically, however, the correlation between hydrophobicity and anesthetic potency is not as precise as in an isolated nerve. Onset of Action • The onset of conduction block in isolated nerves is related to the physicochemical properties of the individual agents. • In vivo latency is also dependent on the dose or concentration of local anesthetic used. • For example, 0.25% bupivacaine possesses a rather slow onset of action, but increasing the concentration to 0.75% results in a significant acceleration of its anesthetic effect. Duration of Action • The duration of action of the various local anesthetics differs markedly. • Procaine and chloroprocaine have a short duration of action. • Lidocaine, mepivacaine, and prilocaine produce a moderate duration of anesthesia, whereas tetracaine, bupivacaine, ropivacaine, and etidocaine have the longest durations. • For example, with procaine, the duration of brachial plexus blockade is 30 to 60 minutes, but up to approximately 10 hours of anesthesia (or at least analgesia) is common for brachial plexus blockade with bupivacaine or ropivacaine. Factors Influencing Anesthetic Activity in Humans • Dosage of Local Anesthetic • As the dosage of local anesthetic is increased, the probability and duration of satisfactory anesthesia increase and the time to onset of block is shortened. • The dosage of local anesthetic can be increased by administering either a larger volume or a more concentrated solution. Addition of Vasoconstrictors • Vasoconstrictors, usually epinephrine (5 µg/mL or 1 : 200,000), are frequently included in local anesthetic solutions to decrease the rate of vascular absorption, thereby allowing more anesthetic molecules to reach the nerve membrane and thus improve the depth and duration of anesthesia, as well as to provide a marker for inadvertent intravascular injection. Site of Injection • The most rapid onset but the shortest duration of action occurs after intrathecal or subcutaneous administration of local anesthetics. • The longest latencies and durations are observed after brachial plexus blocks. • For example, intrathecal bupivacaine will usually produce anesthesia within 5 minutes that will persist for 3 to 4 hours. • However, when bupivacaine is administered for brachial plexus blockade, the onset time is approximately 20 to 30 minutes, and the duration of anesthesia (or at least analgesia) averages 10 hours. • These differences in the onset and duration of anesthesia and analgesia are due in part to the particular anatomy of the area of injection, which will influence the rate of diffusion and vascular absorption and, in turn, affect the amount of drug used for various types of regional anesthesia. • The addition of sodium bicarbonate to local anesthetic solutions has also been reported to decrease the onset time of conduction blockade. • An increase in the pH of the local anesthetic solution increases the amount of drug in the uncharged base form, which should enhance the rate of diffusion across the nerve sheath and nerve membrane and result in a more rapid onset of anesthesia. Mixtures of Local Anesthetics • Mixtures of local anesthetics for regional anesthesia are sometimes used in an effort to compensate for the short duration of action of certain rapidly acting agents such as chloroprocaine and lidocaine and the long latency of longer-acting agents such as tetracaine and bupivacaine. • Mixtures of chloroprocaine and bupivacaine theoretically offer significant clinical advantages because of the rapid onset and low systemic toxicity of chloroprocaine and the long duration of action of bupivacaine; however, clinical results in studies of combinations have been mixed. • There are many choices of drugs to produce spinal anesthesia: • procaine (Novocain), • lidocaine (Xylocaine), • mepivacaine (Carbocaine), • tetracaine (Pontocaine), • ropivacaine (Naropin), • levobupivacaine (Chirocaine), • These drugs provide a duration of spinal anesthesia ranging from 45 to 400 minutes and offer two clinical lengths of action: shorter (<90 minutes) and • longer (>90 minutes). • Procaine is one of the oldest spinal anesthetics and originally replaced cocaine as the drug of choice for spinal anesthesia early in the 20th century. • It is used for brief spinal anesthesia (<1 hour) but appears to be used less frequently than lidocaine for shorter spinal anesthesia because of three primary clinical differences. • It is associated with: • a higher frequency of nausea (unexplained cause), • a relatively high anesthetic failure rate, • and a slower time to recovery. • It is often used as a hyperbaric drug in a dose ranging between 50 and 150 to 200 mg in a 10% concentration. • The reason that some anesthesiologists continue in their use of procaine is the lower frequency of back and leg pain after its use than with lidocaine. • Lidocaine is also often chosen for shorter procedures that can be completed in 1.5 hours or less. • It has measurable effect in less than 5 minutes and is most commonly used as the 5% solution in 7.5% dextrose; however, many continue exploring reducing the concentration of the drug during spinal anesthesia. • It is not clear that reducing the concentration of lidocaine affects the incidence of the back and leg pain (called transient neurologic symptoms and formerly called transient radicular irritation) that follows its use for spinal anesthesia. • Transient neurologic symptoms develop most frequently after ambulatory procedures, especially in patients placed in the lithotomy or knee arthroscopy positions. • Although many continue attempts to link these symptoms with subclinical neurologic injury, the evidence for such an association remains elusive. • My use of lidocaine for spinal anesthesia is directed by the following suggestions. • Limit the dose to 60 to 70 mg, inject the dose at a rate exceeding 0.2 mL/sec, keep the needle aperture directed cephalad, and limit use of the drug for continuous spinal techniques as much as practical. • Mepivacaine is another drug useful for spinal anesthesia and is being applied in settings in which lidocaine was used in the past. • The drug-mass ratio for mepivacaine and lidocaine is approximately 1.3 : 1, suggesting that mepivacaine can be used for spinal anesthesia in a 30- to 60-mg dose and typically in the 2% concentration. • In many aspects, mepivacaine is slightly longer-acting lidocaine, with variable reports of lower or equivalent rates of transient neurologic symptoms. • When longer-acting agents for spinal anesthesia are desired, four drugs are available: • tetracaine, bupivacaine, ropivacaine, and levobupivacaine. • Tetracaine: • This drug has an onset of 5 to 10 minutes and is selected for procedures lasting up to 2 to 3 hours when epinephrine is added and up to 5 hours for lower extremity procedures when phenylephrine (0.5 mg) is added as a vasoconstrictor. • Bupivacaine spinal anesthesia is commonly carried out with 0.75% and 0.5% solutions in dextrose, as well as with isobaric forms of the drug, the 0.5% and the 0.75% plain solutions. • The clinical difference between 0.5% tetracaine and 0.75% bupivacaine as hyperbaric solutions is minimal, although more bupivacaine is used than tetracaine. • It appears that when “isobaric” 0.5% and 0.75% bupivacaine are compared, the mass of drug (milligram dose) injected is more important in determining the eventual block height than the volume of isobaric drug administered. • Bupivacaine is appropriate for procedures lasting up to 2 to 2.5 hours. • Ropivacaine is an amide local anesthetic that is frequently used for epidural anesthesia because of experimental evidence of less effect on the cardiac conduction system than occurs with bupivacaine. • With spinal anesthesia, this difference is minimal because small doses are administered. • When compared with bupivacaine, it is estimated to require 1.8 to 2 times the dose to produce a similar clinical effect. • Many believe that it is clinically indistinguishable from bupivacaine when the dose of drug administered is of a mass to produce an equal effect. • Levobupivacaine is the isolated (S)-enantiomer of bupivacaine and is available for use as a spinal anesthetic. • Clinical data suggest that this drug is converted to bupivacaine when used for spinal anesthesia, and for doses ranging from 4 to 12 mg, a volunteer study suggests little clinical difference between levobupivacaine and racemic bupivacaine. • In 80 patients undergoing elective hip replacement and receiving isobaric levobupivacaine (3.5 mL of a 0.5% solution) or isobaric bupivacaine (3.5 mL of a 0.5% solution), their clinical efficacy was judged equivalent. • In a clinical situation in which systemic toxicity is a minimal issue (or the typical spinal anesthetic), the advantage of levobupivacaine over bupivacaine appears to be more theoretical than real. Spinal Anesthetic Additives • Some physicians are concerned that the use of additives, particularly vasoconstrictors, may be risky. • The concept is that epinephrine and phenylephrine have such potent vasoconstrictive action that they place the blood supply of the spinal cord at risk. • There are no human data supporting this theory. Kozody and colleagues have shown that administering subarachnoid epinephrine (0.2 mg) or phenylephrine (5 mg) does not decrease spinal cord blood flow in dogs. • These traditional vasoconstrictors are not the only adrenergomimetic agents being studied. • Clonidine, an α2-agonist, prolongs the motor block associated with tetracaine spinal anesthesia in dogs as much as epinephrine does while prolonging sensory blockade for an even longer interval. • The mechanism for this prolongation may involve vasoconstriction and antinociception from α-adrenergic stimulation. • Another drug investigated for spinal use as an additive is neostigmine. • This acetylcholinesterase inhibitor inhibits the breakdown of acetylcholine and thereby induces analgesia. • It also prolongs and intensifies the analgesia through release of nitric oxide in the spinal cord. • Despite the side effect of nausea and prolongation of motor block when combining it with local anesthetics, it is slowly gaining acceptance clinically. • The interaction of various vasoconstrictors and local anesthetics is better understood. • Traditionally, epinephrine was thought to prolong tetracaine spinal anesthesia but not bupivacaine or lidocaine spinal anesthesia. • This theory was postulated because of differences in the vasodilatory action of the local anesthetic drugs; plain lidocaine and bupivacaine cause vasodilation, whereas plain tetracaine does not. • Since that time it has become clearer that twodermatome regression in the middle to high thoracic dermatomes may be misleading when measuring spinal anesthetic duration in the lower thoracic and lumbar dermatomes. • Some data indicate that lidocaine spinal anesthesia is prolonged by epinephrine when measured by twodermatome regression in the lower thoracic dermatomes and by occurrence of pain at the operative site for procedures carried out at the level of the lumbosacral dermatomes. • When epinephrine has been compared with phenylephrine as a means of prolonging spinal anesthesia, conflicting information has resulted. • Concepcion and coworkers compared epinephrine (0.2 and 0.3 mg) and phenylephrine (1 and 2 mg) added to tetracaine and did not find a difference in increased duration with the two vasoconstrictors. • Caldwell and associates used larger doses of vasoconstrictors, epinephrine at 0.5 mg and phenylephrine at 5 mg, and showed that phenylephrine prolonged tetracaine spinal anesthesia significantly more than epinephrine did . • Phenylephrine has been shown to prolong lidocaine spinal anesthesia, but it appears that the length of prolongation is more similar to that produced with epinephrine rather than significantly longer. • The duration of bupivacaine spinal anesthesia does not appear to be prolonged by phenylephrine. • Whichever local anesthetic solution and additives are selected for subarachnoid injection, special care should be taken to ensure that the clinician knows what substance is being injected and that all procedures have been carried out aseptically Hypobaric and Isobaric Spinal Anesthesia • The density of any solution is the weight in grams of 1 mL of the solution at a standard temperature. • Specific gravity is the ratio of the density of a solution to the density of water. • Baricity is a ratio comparing the density of one solution to another. • If the other solution happens to be water, the baricity will be the same as the specific gravity. • To make a drug hypobaric to CSF, it must be less dense than CSF, with a baricity appreciably less than 1.0000 or a specific gravity appreciably less than 1.0069 (the mean value of the specific gravity of CSF). A common method of formulating a hypobaric solution is to mix tetracaine in a 0.1% to 0.33% solution with sterile water. This makes the baricity of the solution less than 0.9977 and allows clinically useful anesthesia to be induced. In the prone position for anorectal procedures or in the lateral position for hip repairs, 4 to 6 mg of a selected hypobaric dilution is often adequate. There is evidence that the rate of injection (0.02 versus 0.5 mL/sec) of hypobaric (0.2%) tetracaine influences spread of the drug. • Another method of formulating a hypobaric-like solution is to use warmed 0.5% bupivacaine. • Data show that 0.5% bupivacaine warmed to 37°C as opposed to 4°C demonstrates hypobaric characteristics when the block is administered to sitting patients. • The investigators suggest that warmed bupivacaine provides more predictable cephalad spread of the sensory level than a cold or room-temperature drug does. • Another drug that has been investigated as a “clinically” hypobaric spinal drug is 2% lidocaine. • Its physiochemical characteristics make it more similar to an isobaric than a hypobaric drug; however, some clinicians have found it useful in situations generally reserved for hypobaric techniques. • When isobaric spinal anesthesia is planned, the drugs most often chosen across the globe are bupivacaine, ropivacaine, and levobupivacaine (in 0.5% or 0.75% concentrations). • Another drug that can be used is tetracaine. • It is formulated into an isobaric solution by diluting the niphanoid tetracaine crystals (20 mg) with CSF and then injecting the selected mass of drug in an isobaric fashion. موفق و سربلند باشید